These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 7584910)
21. Protection by Ca2+ channel blockers (nifedipine, diltiazem and verapamil) against the toxicity of oxidized low density lipoprotein to cultured lymphoid cells. Nègre-Salvayre A; Salvayre R Br J Pharmacol; 1992 Nov; 107(3):738-44. PubMed ID: 1472971 [TBL] [Abstract][Full Text] [Related]
22. Both HDL3 and HDL2 exert a powerful anti-oxidative and protective effect against acceleration of oxidative modification of LDL by ascorbic acid. Sakuma N; Saeki T; Yajima K; Hibino T; Yoshida T; Mizuno H; Mukai S; Sakata S; Kunimatsu M; Kimura G J Nutr Sci Vitaminol (Tokyo); 2005 Apr; 51(2):75-9. PubMed ID: 16022192 [TBL] [Abstract][Full Text] [Related]
23. Effect of oxidation of low-density lipoprotein on drug binding affinity studied by high performance frontal analysis-capillary electrophoresis. Kuroda Y; Cao B; Shibukawa A; Nakagawa T Electrophoresis; 2001 Oct; 22(16):3401-7. PubMed ID: 11669517 [TBL] [Abstract][Full Text] [Related]
24. LDL oxidizability and antioxidative status of plasma in vegetarians. Nagyová A; Kudlácková M; Grancicová E; Magálová T Ann Nutr Metab; 1998; 42(6):328-32. PubMed ID: 9895420 [TBL] [Abstract][Full Text] [Related]
25. Enhanced susceptibility of low-density lipoprotein to in vitro oxidation in type 1 and type 2 diabetic patients. Beaudeux JL; Guillausseau PJ; Peynet J; Flourie F; Assayag M; Tielmans D; Warnet A; Rousselet F Clin Chim Acta; 1995 Aug; 239(2):131-41. PubMed ID: 8542651 [TBL] [Abstract][Full Text] [Related]
26. Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment. Leitinger N; Pirich C; Blazek I; Endler G; Sinzinger H Atherosclerosis; 1996 Oct; 126(2):305-12. PubMed ID: 8902156 [TBL] [Abstract][Full Text] [Related]
27. Effect of ascorbate supplementation on low density lipoprotein oxidation in smokers. Fuller CJ; Grundy SM; Norkus EP; Jialal I Atherosclerosis; 1996 Jan; 119(2):139-50. PubMed ID: 8808491 [TBL] [Abstract][Full Text] [Related]
28. Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. Stefanutti C; Di Giacomo S; Vivenzio A; Isacchi GC; Masella R; Caprari P; Varì R; Tarzia A; Mosiello A; Cantafora A Clin Sci (Lond); 2001 Feb; 100(2):191-8. PubMed ID: 11171288 [TBL] [Abstract][Full Text] [Related]
29. Oxidation resistance of LDL in hypertriglyceridaemic patients treated with ciprofibrate. Nagyová A; Raslová K; Ginter E Physiol Res; 1998; 47(3):185-90. PubMed ID: 9803483 [TBL] [Abstract][Full Text] [Related]
30. Resveratrol inhibits copper ion-induced and azo compound-initiated oxidative modification of human low density lipoprotein. Zou JG; Huang YZ; Chen Q; Wei EH; Hsieh TC; Wu JM Biochem Mol Biol Int; 1999 Jun; 47(6):1089-96. PubMed ID: 10410255 [TBL] [Abstract][Full Text] [Related]
31. A rapid method for measurement of the susceptibility to oxidation of low-density lipoprotein. McDowell IF; McEneny J; Trimble ER Ann Clin Biochem; 1995 Mar; 32 ( Pt 2)():167-74. PubMed ID: 7785944 [TBL] [Abstract][Full Text] [Related]
32. Effects of Ca2+ antagonists on motor activity and the dopaminergic system in aged mice. Kurosaki R; Akasaka M; Michimata M; Matsubara M; Imai Y; Araki T Neurobiol Aging; 2003; 24(2):315-9. PubMed ID: 12498965 [TBL] [Abstract][Full Text] [Related]
33. Mechanism of high-density lipoprotein subfractions inhibiting copper-catalyzed oxidation of low-density lipoprotein. Huang JM; Huang ZX; Zhu W Clin Biochem; 1998 Oct; 31(7):537-43. PubMed ID: 9812173 [TBL] [Abstract][Full Text] [Related]
34. Effect of ursodeoxycholic acid on copper induced oxidation of low density lipoprotein. Geetha A; Surendran R Pharmazie; 2005 Aug; 60(8):609-13. PubMed ID: 16124405 [TBL] [Abstract][Full Text] [Related]
35. Effect of tea flavonoid supplementation on the susceptibility of low-density lipoprotein to oxidative modification. Ishikawa T; Suzukawa M; Ito T; Yoshida H; Ayaori M; Nishiwaki M; Yonemura A; Hara Y; Nakamura H Am J Clin Nutr; 1997 Aug; 66(2):261-6. PubMed ID: 9250103 [TBL] [Abstract][Full Text] [Related]
36. Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization. Tertov VV; Sobenin IA; Gabbasov ZA; Popov EG; Jaakkola O; Solakivi T; Nikkari T; Smirnov VN; Orekhov AN Lab Invest; 1992 Nov; 67(5):665-75. PubMed ID: 1434544 [TBL] [Abstract][Full Text] [Related]
37. Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial. Leonetti G; Curr Med Res Opin; 2005 Jun; 21(6):951-8. PubMed ID: 15969895 [TBL] [Abstract][Full Text] [Related]
38. Fatty acid composition and the oxidation of low-density lipoproteins. Corboy J; Sutherland WH; Ball MJ Biochem Med Metab Biol; 1993 Feb; 49(1):25-35. PubMed ID: 8439448 [TBL] [Abstract][Full Text] [Related]
39. Low density lipoprotein composition and oxidizability in coronary disease--apparent favourable effect of beta blockers. Croft KD; Dimmitt SB; Moulton C; Beilin LJ Atherosclerosis; 1992 Dec; 97(2-3):123-30. PubMed ID: 1361323 [TBL] [Abstract][Full Text] [Related]
40. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients. Sanguinetti SM; Brites FD; Fasulo V; Verona J; Elbert A; Wikinski RL; Schreier LE Diabetes Nutr Metab; 2001 Feb; 14(1):27-36. PubMed ID: 11345163 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]